Skip to main content
. Author manuscript; available in PMC: 2019 Jul 15.
Published in final edited form as: Clin Cancer Res. 2018 Apr 10;24(14):3433–3446. doi: 10.1158/1078-0432.CCR-17-2793

Figure 1. High NR3C1 (GR) expression is associated with worse outcome in TNBC subtypes.

Figure 1.

Kaplan-Meier estimates of relapse-free survival in patients in the top quartile (versus all others) of tumor NR3C1 expression. NR3C1 expression association with RFS was analyzed in TNBCs classified (1) as (A) basal-like 1 (NR3C1-high n=43, NR3C1-low n=128), (B) basal-like 2 (NR3C1-high n=19, NR3C1-low n=56), (C) mesenchymal (NR3C1-high n=44, NR3C1-low n=131), (D) luminal AR (NR3C1-high n=57, NR3C1-low n=145).